This article was originally published in The Tan Sheet
Executive SummaryCopenhagen-based biotechnology firm Fluxome Sciences secured 100 million Danish krone ($21.3 million under the July 23 conversion rates) in its latest round of financing, the firm announces July 23. Claude J. Stoufs, senior investment manager for Fluxome shareholder Capricorn Venture Partners, says he anticipates the latest capital increase will help Fluxome "become a major player in the field of nutraceutical ingredients based on production by engineered microorganisms." In June, Fluxome announced a partnership with CP Kelco U.S., a division of J.M. Huber, to develop and commercialize fermentation-derived resveratrol for the dietary supplement market, tentatively aiming for a product launch this fall...
You may also be interested in...
Successfully acquired by Colgate-Palmolive on 31 January, Hello quickly made a statement with the launch of a CBD oral-care range and its first go at lip care, CBD Vegan Lip Balm. Available exclusively through Ulta Beauty, the CBD products have the potential to score well with younger consumers interested in natural ingredients, eco-friendly packaging and, of course, cannabis-based innovations.
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.
Amid the ongoing spread of the coronavirus outbreak, China turns to novel and repurposed antiviral drugs but also courts traditional medicines to ease public fear over the largely unknown threat.